{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:20:28Z","timestamp":1768270828028,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma logistics Inc., Panama"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13555-022-00849-0","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T18:02:30Z","timestamp":1670695350000},"page":"269-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data"],"prefix":"10.1007","volume":"13","author":[{"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Dei-Cas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"LopezTello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Garcia-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Yris","family":"Taveras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azucena Hern\u00e1ndez","family":"Rousselin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Lavieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delfina Guadalupe Villanueva","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Rihakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Salibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfran","family":"Pertuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"849_CR1","volume-title":"An atlas of psoriasis","author":"L Fry","year":"2005","unstructured":"Fry L. An atlas of psoriasis. 2nd ed. London: Taylor & Francis; 2005.","edition":"2"},{"key":"849_CR2","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1111\/jdv.14393","volume":"31","author":"AML Hern\u00e1ndez-V\u00e1squez","year":"2017","unstructured":"Hern\u00e1ndez-V\u00e1squez AML, Larrea N, Ciapponi A. Psoriasis in Latin America and the Caribbean: a systematic review. J Eur Acad Dermatol Venereol. 2017;31:1991\u20138.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"849_CR3","doi-asserted-by":"crossref","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et\u00a0al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12;CD011535.","DOI":"10.1002\/14651858.CD011535.pub2"},{"key":"849_CR4","doi-asserted-by":"crossref","unstructured":"Sbidian E, Chaimani A, Afach S, et\u00a0al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1;CD011535.","DOI":"10.1002\/14651858.CD011535.pub3"},{"key":"849_CR5","first-page":"1","volume":"33","author":"AB Gottlieb","year":"2020","unstructured":"Gottlieb AB, Wu JJ, Griffiths CEM, et al. Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. J Dermatolog Treat. 2020;33:1\u20139.","journal-title":"J Dermatolog Treat."},{"key":"849_CR6","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et\u00a0al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348.","journal-title":"N Engl J Med"},{"key":"849_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et\u00a0al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371:326\u201338.","journal-title":"N Engl J Med"},{"key":"849_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et\u00a0al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet"},{"key":"849_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"849_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s12325-017-0521-z","volume":"34","author":"SZE Adsit","year":"2017","unstructured":"Adsit SZE, Sofen H, et al. Secukinumab is efficacious and safe in Hispanic patients with moderate-to-severe plaque psoriasis: pooled analysis of four phase 3 trials. Adv Ther. 2017;34:1327\u201339.","journal-title":"Adv Ther."},{"key":"849_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjd.15706","volume":"177","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Luger T, Thaci D, et\u00a0al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177:1033\u201342.","journal-title":"Br J Dermatol"},{"key":"849_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/09546634.2019.1603361","volume":"31","author":"BE Strober","year":"2020","unstructured":"Strober BE, Germino R, Guana A, et\u00a0al. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. J Dermatolog Treat. 2020;31:333\u201341.","journal-title":"J Dermatolog Treat"},{"key":"849_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bjd.18981","volume":"183","author":"ZZN Yiu","year":"2020","unstructured":"Yiu ZZN, Mason KJ, Hampton PJ, et\u00a0al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183:294\u2013302.","journal-title":"Br J Dermatol"},{"key":"849_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jdv.16632","volume":"35","author":"M DE Augustin","year":"2021","unstructured":"DE Augustin M, Mrowietz U, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2021;35:431\u201340.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"849_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/jdv.15962","volume":"34","author":"DKA Tha\u00e7i","year":"2020","unstructured":"Tha\u00e7i DKA, von Kiedrowski R, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2020;34:310\u20138.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"849_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12895-019-0087-3","volume":"19","author":"KA Papp","year":"2019","unstructured":"Papp KA, Gooderham M, Beecker J, et\u00a0al. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. BMC Dermatol. 2019;19:9.","journal-title":"BMC Dermatol"},{"key":"849_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jdv.14604","volume":"32","author":"ATD K\u00f6rber","year":"2018","unstructured":"K\u00f6rber ATD, von Kiedrowski R, et al. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. J Eur Acad Dermatol Venereol. 2018;32:411\u20139.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"849_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/1346-8138.14145","volume":"45","author":"M Momose","year":"2018","unstructured":"Momose M, Asahina A, Umezawa Y, Nakagawa H. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: a single-center experience. J Dermatol. 2018;45:318\u201321.","journal-title":"J Dermatol"},{"key":"849_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/14712598.2018.1481503","volume":"18","author":"M Galluzzo","year":"2018","unstructured":"Galluzzo M, Talamonti M, De Simone C, et\u00a0al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18:727\u201335.","journal-title":"Expert Opin Biol Ther"},{"key":"849_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/09546634.2018.1528000","volume":"30","author":"J Notario","year":"2019","unstructured":"Notario J, Deza G, Vilarrasa E, et\u00a0al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat. 2019;30:424\u20139.","journal-title":"J Dermatolog Treat"},{"key":"849_CR21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/14712598.2019.1622678","volume":"19","author":"M Megna","year":"2019","unstructured":"Megna M, Di Costanzo L, Argenziano G, et\u00a0al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19:855\u201361.","journal-title":"Expert Opin Biol Ther"},{"key":"849_CR22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","volume":"32","author":"RLT Bissonnette","year":"2018","unstructured":"Bissonnette RLT, Tha\u00e7i D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32:1507\u201314.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"849_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","volume":"20","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, D\u2019Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020;20:173\u201382.","journal-title":"Expert Opin Biol Ther"},{"key":"849_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdv.16558","volume":"35","author":"J Bagel","year":"2021","unstructured":"Bagel J, Blauvelt A, Nia J, et\u00a0al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol. 2021;35:135\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"60\u201369","key":"849_CR25","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai TF, et\u00a0al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017;76(60\u201369): e69.","journal-title":"J Am Acad Dermatol"},{"key":"849_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jdv.16632","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Dauden E, Mrowietz U, et\u00a0al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2021;35:431\u201340.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"27\u201336","key":"849_CR27","volume":"73","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Leonardi CL, Girolomoni G, et\u00a0al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(27\u201336): e21.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00849-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T18:38:17Z","timestamp":1673030297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00849-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00849-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"9 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}